Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

Completed · Phase 2 · Has a placebo group

Conditions studied: Smoking

In brief

The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.

Key facts

Study ID

NCT01730846

Run by

Yale University

People needed

35

Starts

2013-02-01

Expected to finish

2016-11-01

Last updated by the study team

2018-02-20

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages 18-60
• Able to read and write English
• Smoker
• Motivated to Quit Smoking

You may not qualify if…

• Any significant current medical conditions that would contraindicate smoking
• Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or dependence of other substances, other than nicotine dependence or alcohol abuse
• Positive test results at intake appointment on urine drug screens for illicit drugs
• Past 30 day use of psychoactive drugs including anxiolytics and antidepressants
• Women who are pregnant or nursing
• Suicidal, homicidal or evidence of current severe mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders
• Participants who have donated blood within the past 6 weeks
• Individuals who are currently taking other medications prescribed for smoking cessation
• Specific exclusions for administration of doxazosin or any alpha blocker

Where it is running

• Yale Center for Clinical Investigations, Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.